Gastric cancer
Drug research and approvals for gastric cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 737 studies of gastric cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 30 drug trials for it since 2013, FDA has 15 approved and 91 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 737
- Trials authorized in Canada: 30
- FDA orphan approvals: 15
- EU medicines: 3
- Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction…NCT07933471 · Phase 2 · Beijing Tsinghua Chang Gung Hospital · starts Aug 5, 2026
- A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsNCT07923214 · Phase 1 · Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · starts Jul 2, 2024
- Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or…NCT07920224 · Phase 2 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · starts Jul 19, 2025
- Epinephrine 1:100,000 Versus 1:500,000 During Gastric Endoscopic Submucosal DissectionNCT07920068 · Not applicable · Unidade Local de Saúde do Alto Ave, EPE · starts Jul 30, 2025
- 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor DiagnosisNCT07914764 · Not reported · Nanjing First Hospital, Nanjing Medical University · starts Aug 1, 2026
- A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted ImmunochemotherapyNCT07911280 · Phase 2 · Samsung Medical Center · starts Oct 6, 2026
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNCT07909031 · Phase 1 / Phase 2 · Crescent Biopharma, Inc. · starts Oct 21, 2026
- Development and Utilization of an Integrated Clinical Genomic DatabaseNCT07911267 · Not reported · Samsung Medical Center · starts Dec 6, 2024
- A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.NCT07903415 · Phase 1 · Pfizer · starts Nov 5, 2026
How its trials ended
2,355 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 371 whose ending is known, 38% met their primary endpoint, 12% missed it and 50% stopped early.
- Completed, result not reported69630%
- Ongoing66928%
- Status unknown61926%
- Met its primary endpoint1406%
- Stopped: other or unclear874%
- Stopped: enrollment or feasibility472%
- Missed its primary endpoint462%
- Stopped: sponsor or business decision281%
- Stopped: lack of efficacy161%
- Stopped: safety6<1%
- Stopped: funding1<1%
| Sep 23, 2026 | A randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab…Cadonilimab (AK104) | Akeso Pharma Co., Ltd. | Pending |
| Dec 18, 2025 | Rosetta gastric-204: a blinded, randomized, phase 2/3 study of pumitamig in combination with chemotherapy versus nivolumab in combination with chemotherapy in…Pumitamig (BMS-986545; BNT327) / Opdivo [nivolumab (BMS-936558)] / Calcium… | Bristol-Myers Squibb | Ongoing |
| Sep 19, 2025 | A phase III, multicentre, randomised controlled study of sonesitatug vedotin in combination with fluoropyrimidine with or without rilvegostomig in first-line…Sonesitatug vedotin (AZD0901) / Rilvegostomig (AZD2936) | AstraZeneca Pharmaceuticals | Ongoing |
| May 30, 2025 | A phase 3, double-blind, randomized study of zolbetuximab in combination with pembrolizumab and chemotherapy (capox or mfolfox6) in first-line treatment of…Zolbetuximab / Pembrolizumab | Astellas Pharma | Pending |
| Mar 5, 2025 | A multicenter, randomized, open-label, phase 3 trial of trastuzumab deruxtecan (enhertu®) plus chemotherapy plus or minus pembrolizumab versus chemotherapy…Enhertu / Keytruda / Herzuma / Herceptin / Kanjinti / Trazimera /cisplatin… | Daiichi Sankyo | Ongoing |
| Oct 25, 2024 | A phase 2 randomized study to evaluate the safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, leucovorin, and budigalimab as…Telisotuzumab adizutecan (ABBV-400) / Budigalimab (ABBV-181) / Fluorouracil /… | AbbVie | Ongoing |
| Jul 26, 2024 | A randomized, phase III study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab, chemotherapy, and…Rilvegostomig (AZD2936) / Trastuzumab deruxtecan (t-dxd) / Capecitabine /… | AstraZeneca Pharmaceuticals | Ongoing |
| Oct 20, 2022 | A randomized, open-label, multicenter phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in participants with…Zimberelimab (AB122) / Domvanalimab (AB154) / Oxaliplatin / Leucovorin /… | Arcus Biosciences | Closed |
| Nov 16, 2021 | Pioneering pre- and post-operative integrative care to improve thoracic cancer quality of care: the thoracic peri-operative integrative surgical care…Vitamin D | Ottawa Hospital Research Institute | Ongoing |
| Aug 12, 2021 | A randomized trial comparing early local chemoradiation therapy +/- surgery versus systemic therapy for patients with esophageal or gastric cancer with…Fluorouracil | Research Institute of The McGill University Health Centre | Ongoing |
| Aug 25, 2026 | TevimbraIn combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment for adults… | BeOne Medicines USA, Inc. | Approved |
| Aug 25, 2026 | Ziihera(1) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr, for the first-line treatment of adult… | Jazz Pharmaceuticals Ireland Limited | Approved |
| Nov 25, 2025 | ImfinziIn combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by… | AstraZeneca Pharmaceuticals | Approved |
| Dec 26, 2024 | TevimbraIn combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of adults with unresectable or… | BeOne Medicines USA, Inc. | Approved |
| Oct 18, 2024 | VyloyIn combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced… | Astellas Pharma Global Development Inc. | Approved |
| Nov 16, 2023 | KeytrudaIn combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced… | MSD International Business GmbH | Approved |
| May 20, 2021 | OpdivoAdjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who… | Bristol-Myers Squibb Company | Approved |
| May 5, 2021 | KeytrudaIn combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with… | MSD International Business GmbH | Approved |
| Apr 16, 2021 | OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic… | Bristol-Myers Squibb Company | Approved |
| Apr 16, 2021 | OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic… | Bristol-Myers Squibb Company | Approved |
| Jan 15, 2021 | EnhertuTreatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who… | Daiichi Sankyo, Inc. | Approved |
| Feb 22, 2019 | LonsurfLONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously… | Taiho Oncology, Inc. | Approved |
| Sep 22, 2017 | KeytrudaKEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction… | MSD International Business GmbH | Approved |
| Nov 5, 2014 | CyramzaTreatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after… | Eli Lilly and Company | Approved |
| Apr 21, 2014 | CyramzaCYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction… | Eli Lilly and Company | Approved |
| Nov 15, 2023 | HerwendaTrastuzumab · biosimilar | Sandoz GmbH | EMA ↗ |
| Dec 19, 2014 | CyramzaRamucirumab | Eli Lilly Nederland B.V. | EMA ↗ |
| Mar 14, 2011 | TeysunoTegafur; gimeracil; oteracil | Nordic Group B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA